Cyrona Cell uses Wharton’s Jelly mesenchymal cells that have been derived from infant umbilical cords as they can:

As Degenerative Disc disease occurs due to the failure of the cartilaginous endplates, chondrocytes, and proteoglycans to maintain the structural integrity of the outer casings of discs (the annulus fibrosus), the aim of cell therapy is to facilitate the transportation of nutrients into discs, increase disc height and pressure, prevent chondrocytes from dying, and regenerate the intervertebral discs.
Scientifically-Proven Results
|
University/Centre |
Results |
|
|
2006 |
Tokai University School of Medicine, Japan |
Increased disc height by 91% and MRI signal intensity by 81%, indicating that water had been attracted to the region. |
|
2011 |
Centro Médico Teknon, Spain |
Decreased pain and disability by 85%. |
|
2014 |
General Hospital of Armed Police Force, China |
Immediate improvement in pain and functionality. Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) remained decreased two years after therapy. |
|
2014 |
Mesoblast Limited, Australia |
Decreased lower back pain and improved functionality for 12 months, decreased dependence on pain medication, increased disc stability, and decreased the need for surgical and non-surgical interventions. |
|
2015 |
Rocky Mountain Associates in Orthopedic Medicine and the Orthopedic Stem Cell Institute, United States |
Decreased Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) scores from 56.5 to 25.0 and 79.3 to 33.2, respectively, for 12 months. |
|
2015 |
Cha University, South Korea |
Significantly increased disc water content in 12 weeks. |
|
2015 |
Navy General Hospital, China |
Significantly improved and halt the progression of disc height reduction as well as promoted the formation of disc matrix components (aggrecan and type II collagen), proteins that are critical for providing discs with structure and support. |
Achieving high standards in our work is of paramount importance to us. As such, we only produce and use premium grade passage 1 (P1) and passage 2 (P2) Wharton’s Jelly mesenchymal stem cells in all our therapy programmes. These cellular products have also been thoroughly screened and analysed in accordance with the requirements of The International Society for Cellular Therapy prior to use.
We also use the latest in cellular research and technologies to tailor our therapy programmes according to the needs of the individual. Furthermore, our microbiology and clinical team as well as our extensively experienced board-certified physicians are geared towards your safety and wellbeing.
All our therapy programmes are conducted using premium grade P1 and P2 Wharton’s Jelly mesenchymal cells and by board-certified experienced specialists. All patients are also provided with pre-transfusion analysis reports of any and all cellular and supplementary products used during treatment.
International patients will be provided with airport transfer services and accommodations as well as in-city transportation to and from every therapy session.
As no two people are alike, our specialists review each patient’s medical reports before developing the best treatment protocol to addresses their unique needs. Therefore, before speaking to one of our Customer Service Representatives, it is best to have the following handy:
Download our eBook and receive our weekly in-depth and exclusive newsletter about Degenerative Disc Disease.